Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avadel Pharmaceuticals Q2 2024 Adj EPS $(0.14) Beats $(0.16) Estimate, Sales $41.50M Beat $37.53M Estimate

Author: Benzinga Newsdesk | August 08, 2024 07:10am
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $41.50 million which beat the analyst consensus estimate of $37.53 million by 10.56 percent. This is a 2.67K percent increase over sales of $1.50 million the same period last year.

Posted In: AVDL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist